Genesis R&D Extends Use of MorphoSys' HuCAL Antibodies for Autoimmune Rx Development

Oct 08, 2007

NEW YORK (GenomeWeb News) — MorphoSys today said Genesis Research and Development will continue using HuCAL-based antibodies in its drug-development research.

New Zealand-based Genesis will use the antibodies, developed by MorphoSys’ AbD Serotec segment, against the target molecule FGFR5 for validations and pre-clinical studies for its Zyrogen drug, which is being studied for certain autoimmune diseases, according to Genesis’ website.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

This Week in PLOS

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.

A Winning Diagnostic

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

Science in Africa Unevenly Funded

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

Not Enough Progress?

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

Main menu